



BIODIEM LTD
ABN 20 096 845 993
Suite 3, Level 11,
470 Collins Street,
Melbourne, Victoria, 3000
Australia
Phone: +613 9613 4100
Web: www.biodiem.com

ASX Announcement

BioDiem to present at Hong Kong biotech investment forum

Melbourne, 4 June 2013: Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) is presenting to Asian investors as part of biotech and partnering forum *Asia Biotech Invest 2013*, held at the Sheraton Hotel and Towers in Hong Kong from June 3 – 5, 2013.

BioDiem CEO Julie Phillips will present on BioDiem's commercial programs and technology pipeline, business model and investment and partnership opportunities at 10.15am (HKT) on Tuesday 4 June.

"Asia Biotech Invest is a key event for investment and capital raising, bringing together potential investors and biotech leaders. It provides an opportunity to build awareness of our commercial flu programs and technology portfolio in a strong Asian market," CEO Julie Phillips said.

"Our influenza vaccine technology is already generating revenues through partnerships in India and China. The next commercial opportunity is our patented antimicrobial, BDM-I, which is currently in preclinical proof-of-concept studies for a range of hard-to-treat infectious diseases. We have made significant progress in the last six months and I look forward to sharing these insights with potential partners and investors."

The information presented at Asia Biotech Invest will be available on the ASX post-event. For additional information, please visit www.biodiem.com

ENDS

About BioDiem Ltd

BioDiem (ASX: BDM) is an ASX-listed biopharmaceutical company which is developing vaccines and antimicrobials for the treatment or prevention of infectious diseases, and related cancers. Their lead technology is the LAIV (Live Attenuated Influenza Virus) used for seasonal and pandemic influenza vaccines, and which is administered intranasally. A project develop a therapeutic hepatitis vaccine, targeting hepatitis D and B, is underway at the University of Canberra. BioDiem has an antimicrobial, BDM-I, which is in preclinical development for fungal and bacterial diseases as well as schistosomiasis, tuberculosis and protozoal infections. The company also has SAVINE (scrambled antigen) technology which is in development to address tuberculosis and also Epstein-Barr virus (EBV) related disease including nasopharyngeal cancer. BioDiem also has a retinal product, BDM-E, which is in development for retinitis pigmentosa and is available for outlicence.

BioDiem's research is ongoing in partnerships with internationally recognised laboratories and commercial groups.

For additional information, please visit www.biodiem.com

Contact

Investors

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com

Media

Shevaun Cooper
Buchan Consulting
Phone +61 3 8866 1218 / +61 (0) 421 760 775
Email scooper@buchanwe.com.au



Therapies for major infectious diseases and related cancers

Asia Biotech Invest 2013 : Hong Kong 4 June 2013

Julie Phillips, CEO
www.biodiem.com
(ASX:BDM)

BioDiem Agenda



Challenges



Company Focus




Current Achievements



Future Investment Opportunity

BioDiem Challenges



BioDiem Challenges



Increasing resistance

To antibiotics – major concern healthcare systems worldwide



Hard to treat

Fungal infections, affecting vulnerable patients



No vaccines available

For worldwide diseases eg. hep B, C and D




Product pipelines diminish

Large Pharma focus on innovation, as product pipelines diminish > acquisition opportunities


BioDiem Company Focus




BioDiem Business Model



BioDiem Business Model



BioDiem Business Model



Phase I trials

Testing the drug on healthy volunteers



Phase II trials

Testing the drug on a small number of patients with the disease



Phase III trials

Testing the drug on hundreds/thousands of patients with the disease

BioDiem Three core development programs



Target



Core Technology

Influenza vaccines (seasonal and pandemic)



LAIV vaccine – licensed in multiple countries

Vaccine development platforms
Hepatitis B/D, nasopharyngeal carcinoma, TB



SAVINE technology, LAIV viral vector, flavi and hepatitis virus technologies for novel therapeutic vaccines

Infectious disease therapies
Fungal disease: difficult to treat
Bacterial disease: MRSA
Parasites: Schistosomiasis



BDM-I antimicrobial compound

BioDiem Influenza Vaccines



Live Attenuated Influenza Virus: LAIV

Advantages



Needle-free nasal delivery

No trained personnel and blood/sharps precautions unnecessary



Extensive clinical and market experience > 100m doses

In Russia efficacy and safety in >500,000 adults/140,000 children



Broader immune response

Than seen with inactivated influenza vaccines



High yields

In egg-based or cell-based production (with no reliance on eggs)



No adjuvant required

Live Attenuated Influenza Virus: LAIV

Product	Disease Targets	Current Partners	Development Status
LAIV (Influenza)	Influenza – Seasonal & Pandemic	WHO SII (India) BCHT (China) IEM (Russia)	Marketed with license revenues \$A1.3m FY2012 Phase II (cell-based technology) Seeking growth & out-licensing in more markets
	Avian (Bird) Flu	IEM/WHO	Clinical trials completed in Thailand and Russia

BioDiem Vaccine development platforms



BioDiem LAIV Vector & SAVINE

Opportunity to target multiple infectious diseases and related cancers



LAIV Vector
(Vaccine delivery)




SAVINE
(Custom vaccines)

Disease Targets	Vaccine development	Nasopharyngeal carcinoma (NPC), tuberculosis (TB)
Current Partners	VIVALIS	In-house
Development Status	First stage of development project completed	Seeking partner for more advanced data in animals

BioDiem Hepatitis Vaccine (therapeutic)



Hepatitis D



Hepatitis B




Hepatitis C

Rights licensed from the University of Canberra

R&D program underway

BioDiem Dengue Fever vaccine (therapeutic)

Rights licensed from the Australian National University



Technology
licensed



Vaccine effect
demonstration



Publication
pending



Extension into other
mosquito-borne
disease targets

BioDiem Infectious disease therapies



BioDiem BDM-I antimicrobial disease targets

BDM-I currently in development as treatment against

- 'superbugs' such as antibiotic-resistant bacteria incl. TB, and others
- **hard-to-treat fungal** infections

Product	Disease Targets	Current Partners	Development Status
BDM-I (Antimicrobial)	Bacterial infections (tuberculosis, others)	US government backed research institutions	Entered <i>in vivo</i> testing in 2013
	Fungal infections	US government backed research institutions	Entered <i>in vivo</i> testing in 2013
	Parasitic diseases (schistosomiasis, others)	QIMR program	Entered <i>in vivo</i> testing in 2013




Expanding Global Partnerships and Alliances



Global partnering & commercialisation network



BioDiem Current Achievements






BioDiem License & Pipeline Portfolio

Vaccine Development Pipeline

	Research	Preclinical	Phase I	Phase II	Phase III	Marketed
Influenza vaccines (Seasonal & Pandemic)	Cell based production					
	Egg based production					
	Licensed to World Health Organisation for public market in Developing Countries Licensed to Serum Institute of India and Changchun BCHO Biotech Co. for certain Developing Country private markets					
LAIV Viral Vector platform						
Hepatitis D PLATFORM (Hepatitis D/Hepatitis B therapeutic vaccine)						
Flavivirus PLATFORM (Dengue fever, West Nile, Murray River encephalitis)						
SAVINE antigen technology (Tuberculosis, NPC)						

BioDiem Pipeline Portfolio

BDM-I Development Pipeline

	Research	Preclinical	Phase I	Phase II	Phase III	On market
Bacterial targets (Biological warfare agents, MSRA, tuberculosis, other)						
Fungal targets (Difficult to treat fungi, incl. Scedosporium, Pneumocystis & Candida spp.)						
Parasitic targets (schistosomiasis, other)						

BioDiem Partnership Portfolio

Expanding Global Partnership Network



WHO



National Institutes
of Health

National Institutes
of Health (USA)



PATH (Program for
Appropriate Technology
in Health)



Centres for Disease Control
and Prevention (US)



Changchun BCHT
Biotech Co, China
(BCHT)

Vivalis

VIVALIS
(now Valneva)



Serum Institute of
India (SII)



IEM
(St Petersburg,
Russia)



US Army Research Institute of
Infectious Diseases (USAMRIID)



Queensland Institute of
Medical research (QIMR)




UNIVERSITY OF
CANBERRA
AUSTRALIA'S CAPITAL UNIVERSITY

University of
Canberra, Australia

BioDiem Future Investment Opportunity



BioDiem Market Size Potential



BioDiem BioDiem Limited

As at 30 May 2013 (\$AUD)

Market Cap	\$4.26 M
52 week range	\$0.025 – \$0.079
Cash as of 31-03-13	\$1.819M
Shares	142,105,934
Shareholders	919
Listed Options	24,638, 574

Hugh Morgan AC



Chairman

Julie Phillips



CEO

Prof Larisa Rudenko



Non-executive
Director

Prof Arthur Li



Non-executive
Director

Don Brooks



Non-executive
Director

BioDiem Next 12 months



Additional
license revenues




Clinical
trial results




Vector program



Results from
expanded studies



Hepatitis
vaccine progress



Expand sales and
use of LAIV in new
territories



BDM-I testing in
animal models



Completion of BDM-E
out-licensing or sale



Therapies for major infectious diseases and related cancers

Asia Biotech Invest 2013 : Hong Kong 4 June 2013

Julie Phillips, CEO
www.biodiem.com
(ASX:BDM)